Sugammadex

DrugBank ID: DB06206

Summary

Metric	Value
Total Predictions	50
KG+DL (Dual Validated)	0
DL Only	50
KG Only	0

Predictions

Indication	Score	Source
breast fibrocystic disease	0.9849	DL
Prinzmetal angina	0.9839	DL
peripheral arterial disease	0.9806	DL
apocrine adenosis of breast	0.9782	DL
blunt duct adenosis of breast	0.9782	DL
thrombotic disease	0.9750	DL
tendinitis	0.9742	DL
antithrombin deficiency type 2	0.9742	DL
benign mammary dysplasia	0.9742	DL
female breast carcinoma	0.9730	DL
factor 5 excess with spontaneous thrombosis	0.9730	DL
epiglottitis	0.9726	DL
ischemic disease	0.9725	DL
angiodysplasia	0.9722	DL
idiopathic granulomatous myositis	0.9719	DL
myositis fibrosa	0.9719	DL
hemoglobinopathy	0.9717	DL
fibrocartilaginous embolism	0.9712	DL
venous thromboembolism	0.9712	DL
breast adenosis	0.9709	DL
heparin cofactor 2 deficiency	0.9706	DL
peripheral vascular disease	0.9701	DL
non-inflammatory vasculopathy	0.9698	DL
lactation disease	0.9692	DL
vascular ectasia	0.9668	DL
congenital renal artery stenosis	0.9661	DL
breast abscess	0.9658	DL
fat necrosis of breast	0.9658	DL
fibromyalgia	0.9658	DL
vein disease	0.9648	DL
thrombophilia	0.9645	DL
intermittent vascular claudication	0.9643	DL
myocardial infarction	0.9642	DL
laryngitis	0.9629	DL
malignant pleural mesothelioma	0.9623	DL
partial deletion of the short arm of chromosome 16	0.9615	DL
Lyme disease	0.9582	DL
coronary thrombosis	0.9579	DL
hemolytic anemia due to glucophosphate isomerase deficiency	0.9571	DL
beta-thalassemia with other manifestations	0.9570	DL
posteroinferior myocardial infarction	0.9562	DL
posterolateral myocardial infarction	0.9562	DL
septal myocardial infarction	0.9555	DL
inclusion body myositis	0.9540	DL
intracranial arteriosclerosis	0.9538	DL
vascular insufficiency disorder	0.9501	DL
priapism	0.9501	DL
malignant epithelioid mesothelioma	0.9489	DL
pyropoikilocytosis, hereditary	0.9487	DL
malignant visceral pleura tumor	0.9483	DL

External Links

Disclaimer
Predictions are for research purposes only and do not constitute medical advice.